在平分相同的造血细胞移植中调节方案的现状
Junichi Sugita1, Masamitsu Yanada2
1Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Hematology (Amsterdam, Netherlands)
|March 21, 2024
概括
移植后的循环胺 (PTCY) 是与 haploidentical 相关的造血细胞移植 (Haplo-HCT) 的标准. 最佳调节方案仍在调查中,以改善结果并减少基于PTCY的Haplo-HCT的复发率.
科学领域:
- 造血干细胞移植 造血干细胞移植
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 由于有效的移植对宿主疾病 (GVHD) 预防,日益多地使用与 Haplo-identical 相关的造血细胞移植 (Haplo-HCT).
- 移植后循环胺 (PTCY) 是目前在Haplo-HCT中GVHD预防的标准,其结果与其他供体来源相似.
- 调节方案对于瘤根除和免疫抑制至关重要,以确保在Haplo-HCT.中植入.
研究的目的:
- 对基于PTCY的Haplo-HCT.CT中使用的调节方案的现有文献进行审查.
- 讨论基于PTCY的Haplo-HCT中的各种调节方案的演变和研究.
- 突出了对基于PTCY的Haplo-HCT建立最佳调节策略的持续需求.
主要方法:
- 对基于PTCY的Haplo-HCT的调节方案的现有文献的审查.
- 对接受基于PTCY的Haplo-HCT的患者数据的分析.
- 讨论各种调节方案,包括非骨髓退化,骨髓退化和减少强度的方法.
主要成果:
- 最初基于PTCY的Haplo-HCT使用了非骨髓衰变条件 (fludarabine,环胺,低剂量TBI),但高复发率需要加强治疗方案.
- 为了改善结果,已经探索了各种肌肉衰变和减少强度的调节方案.
- 基于PTCY的Haplo-HCT的最佳调节方案尚未最终确定.
结论:
- 基于PTCY的Haplo-HCT的最佳调节方案是一个需要进一步研究和共识的领域.
- 对条件化策略的持续调查对于最大限度地发挥基于PTCY的Haplo-HCT的好处至关重要.
- 在临床实践中,解决最佳调节方案对于推进基于PTCY的Haplo-HCT在临床实践中至关重要.
相关概念视频
01:22Bone Marrow Sampling and Transplants
328
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
328
01:01Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
01:19Multipotency of Hematopoietic Stem Cells
3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K
01:21Lineage Commitment
3.0K
Commitment is the process whereby stem cells:
3.0K
01:21Stem Cell Therapy for Tissue Regeneration
4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
01:21Hematopoiesis
5.3K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.3K